FDA drug chief Janet Woodcock gave a small opening to the agency factoring drug price spikes in how it queues generic drug approvals, telling a Senate panel Thursday that such a policy might be possible if HHS came up with a “bullet proof” way of defining a price spike. Woodcock initially appeared to reject the notion when queried by Sen. Elizabeth Warren (D-MA) at a health committee hearing, but later indicated a potential opening to factor price spikes in agency...